At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 50 enrolled

Drug / intervention

PF-06480605drug

Likely dose

PF-06480605 500 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02840721

NCT02840721Phase 2Completed

Compare CT.gov

A PHASE 2A, MULTICENTER, SINGLE ARM, OPEN- LABEL, TWO-STAGE, STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06480605 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Telavant, Inc.·interventional·Posted Jul 21, 2016·Updated Oct 23, 2023

In Brief

A Phase 2 clinical trial evaluating PF-06480605 for Colitis, Ulcerative. Completed, enrolled 50 participants across 28 sites in 6 countries.

Detailed Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of PF-06480605 in subjects with moderate to severe ulcerative colitis.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsColitis, Ulcerative

CountriesBelgium, Italy, Netherlands, Poland, South Korea, United States

CollaboratorsPfizer

Timeline

Phase 2CompletedFinished

2017201820192020202120222023202420252026

First PostedJul 2016

Enrollment StartOct 2016

Primary CompletionMay 2018

Study CompletionAug 2018

TodayJul 2026

First PostedJul 21, 2016

Enrollment StartOct 26, 2016

Primary CompletionMay 31, 2018

Study CompletionAug 30, 2018

TodayJul 2, 2026

Enrollment to primary: 1.6 yearsPosted 9.9 years ago

Interventions

PF-06480605drug

PF-06480605 500 mg IV Q2W x 7 Doses